Diligence memo · auto-generated · as of July 2, 2026
Mytos, Inc.
Mytos, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Mytos, Inc. operates in Biotech, based in NEWARK, England, United Kingdom. Robotic human cell manufacturing
Sub-sector tags: Automation, Biotech, Biotechnology, Hardware, IoT.
Capital & rounds (filed)filed
Mytos, Inc. has raised $18M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2023-09-20.
Most recent recorded round closed around 2023-09-20.
Valuation (modeled)modeled
Provath models Mytos, Inc. at approximately $180M (range $36M–$373M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.16× the median modeled value of Series B Biotech companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (116% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.8 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 88% of Biotech peers (233 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Watchmaker Genomics, Inc., ZBiotics Co, Siren Biotechnology, Inc., Invert, Inc., AgNovos Bioscience, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.